Sigrid Van Bladel

Who is Sigrid Van Bladel?

Sigrid joined NEA in 1994 as an Associate and became a Partner in 1997. She focuses on biopharmaceuticals and medical device companies. Current board memberships include Acorn Cardiovascular, Kanisa Pharmaceuticals, Neuropace, Spiration and SurgRx. She also works closely with Alexza (NASDAQ: ALXA) and Alsius. Previous board memberships include among others, Myogen (formerly NASDAQ: MYOG, acquired by Gilead – NASDAQ: GILD); Novacept (acquired by Cytyc -NASDAQ: CYTC); Xcel Pharmaceuticals (acquired by Valeant NYSE: VRX): Appriva Medical (acquired by Microvena/EV3), and Sonic Innovations (NASDAQ:SNCI). Prior to joining NEA, Sigrid worked as a Management Consultant at McKinsey and Company and as a Research Associate with the National Science Foundation of Belgium. She received a "Licenciaat" in Chemistry/Biotechnology (summa cum laude) and a PhD (summa cum laude) in Molecular Biology from The University of Ghent, Belgium. She holds an MBA degree from Stanford University.